Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Amarex Clinical Research guides its client to phase II of FDA trials
Tislelizumab is now approved in nine indications in China
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
Company hires life science veteran Jessica Cao to join management team
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Bayer now present in four of the largest biotechnology hubs in the United States
Subscribe To Our Newsletter & Stay Updated
